LifeShield
LifeShield is a hereditary cancer screening platform combining AI-guided NCCN-based risk assessment, at-home 47-gene panel genetic testing, and telehealth genetic counseling, serving individual consumers and employers offering it as a US workplace wellness benefit.
- Company typePrivate
- Founded2026
- HeadquartersNew York, United States
- Headcount1–10
- GTM typeB2B and B2C
- OfferingServices
What LifeShield does
LifeShield operates a hereditary cancer screening platform at lifeshield.ai that combines AI-guided risk assessment, clinical-grade genetic testing, and genetic counseling into a single integrated service. The company serves two primary customer segments: individual consumers concerned about hereditary cancer risk due to family history, Ashkenazi Jewish ancestry, or personal diagnosis, and employers seeking to offer proactive cancer prevention as a voluntary employee wellness benefit. Headquartered in New York, United States, LifeShield operates as LifeShield Technologies, Inc. under a dual direct-to-consumer and B2B2E (employer-sponsored) go-to-market motion.
The core Hereditary Cancer Screening Program is a four-step service: (1) a free 5-minute AI-powered conversational chat that collects family cancer history in plain language; (2) an NCCN Guideline-Based Cancer Risk Report that matches the user's answers against National Comprehensive Cancer Network clinical criteria to determine testing eligibility; (3) AI-Guided Pre-Test Genetic Education that automates informed consent online; and (4) an at-home saliva-based 47-gene hereditary cancer panel test processed in a CLIA-certified laboratory, with results reviewed by a licensed provider and delivered in 2-3 weeks. Optional add-ons include telehealth genetic counseling with Board-Certified Genetic Counselors and cascade testing for relatives of positive cases. The platform is HIPAA- and GINA-compliant and operates exclusively in the United States.
LifeShield generates revenue through three streams. Direct-to-consumer testing is priced at $499 per test, with insurance reimbursement available from Aetna, Blue Cross Blue Shield, Cigna, UnitedHealthcare, and Humana when clinical criteria are met. The B2B employer benefit program charges $5-15 per eligible employee per month on a pay-only-when-used basis with no minimums, and includes HR dashboards, communication materials, and aggregate utilization reporting—LifeShield reports a typical 15-25% first-year employee participation rate and zero out-of-pocket cost for employees who use the benefit. Paid telehealth genetic counseling sessions are processed via Stripe. The company was founded in 2026 per firmographics, operates with 1-10 employees, and has not disclosed funding rounds or revenue figures in the available source material.
LifeShield firmographics
Firmographics- Name
- LifeShield
- Legal name
- LifeShield Technologies, Inc.
- Website
- https://lifeshield.ai
- Company type
- Private
- Founded year
- 2026
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- LifeShield is a hereditary cancer screening platform combining AI-guided NCCN-based risk assessment, at-home 47-gene panel genetic testing, and telehealth genetic counseling, serving individual consumers and employers offering it as a US workplace wellness benefit.
- Ownership category
- akta.pro rank
LifeShield industry classification
Industry- Product category
- Genetic Testing Services
- NAICS
- Testing Laboratories and Services (541380)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)
- akta.pro secondary industry
- Genetic Counseling & Prenatal Testing Telehealth (carrier screening, NIPT counseling) (HLALAHAK)
Keywords
Where LifeShield is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Markets served
LifeShield business model
Business model- GTM type
- B2B and B2C
- Offering type
- Services
- Cost components
- Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure, Supply Chain
Revenue model
- Direct Genetic Testing: Direct consumer payment of $499 for comprehensive hereditary cancer panel genetic testing. Offered after completing free risk assessment and pre-test education when eligibility criteria are met.
- Insurance Reimbursement: Testing covered by major insurance plans when clinical guidelines are met. LifeShield verifies coverage and provides superbill for reimbursement. Accepts Aetna, BCBS, Cigna, UnitedHealthcare, Humana and hundreds of other insurance providers.
- Employer Benefit Program: B2B revenue from employers offering LifeShield as an employee wellness benefit. Employers pay $5-15 per eligible employee per month. LifeShield handles communication, enrollment, education, and aggregate reporting.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Freemium | Pay-as-you-go | Free risk assessment with instant AI-guided results |
| Freemium | Pay-as-you-go | Pre-test education session when eligibility qualified |
| One time/ perpetual license | Pay-as-you-go | Comprehensive 47-gene hereditary cancer panel with at-home testing |
| Subscription | Monthly | Employer-sponsored employee benefit program |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
LifeShield product offering
Product offeringCore offering
LifeShield operates a hereditary cancer screening platform that combines an AI-guided family cancer history assessment with NCCN clinical guideline-based eligibility analysis, at-home 47-gene hereditary cancer panel testing via CLIA-certified laboratories, and telehealth genetic counseling. The service is delivered direct-to-consumer via lifeshield.ai with a freemium assessment funnel, and as an employer-sponsored wellness benefit priced at $5–15 per eligible employee per month.
Product overview
LifeShield offers a unified hereditary cancer screening platform that combines AI-powered risk assessment, clinical-grade genetic testing, and genetic counseling into a single service. The core Hereditary Cancer Screening Program consists of four integrated modules: the AI-Powered Family Cancer History Assessment (free 5-minute chat-based assessment), the NCCN Guideline-Based Cancer Risk Report (instant eligibility determination), AI-Guided Pre-Test Genetic Education (automated consent process), and At-Home Hereditary Cancer Panel Genetic Testing ($499 or insurance-covered saliva test with 47-gene panel). Optional add-on services include Genetic Counseling via telehealth and Cascade Testing for family members. LifeShield also offers an Employer Genetic Testing Program as a workplace benefit. All genetic testing is performed in CLIA-certified laboratories with results reviewed by licensed providers.
Differentiator
Problem solved
Functional benefit
Quantifiable outcome
- Up to 26% risk reduction with early detection of hereditary cancer syndromes
- +6 more outcomes
Companies that use LifeShield
Customer profileNamed customers5 records
Segments3 records
LifeShield technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature4 records
LifeShield partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core.
- AetnacoreMajor health insurance provider accepted for genetic testing reimbursement. LifeShield verifies coverage and provides superbill for reimbursement when clinical guidelines are met.
- Blue Cross Blue Shield (BCBS)coreMajor health insurance provider accepted for genetic testing reimbursement. Coverage varies by plan when NCCN clinical criteria are met.
- CignacoreMajor health insurance provider accepted for genetic testing reimbursement. LifeShield handles insurance verification and provides documentation for claims.
- UnitedHealthcarecoreMajor health insurance provider accepted for genetic testing reimbursement. Coverage determined based on clinical eligibility criteria.
- HumanacoreMajor health insurance provider accepted for genetic testing reimbursement. LifeShield works with members to verify coverage and maximize benefits.
- StripecorePayment processing provider for genetic counseling session bookings. LifeShield does not store credit card numbers. Used for secure transaction handling.
- CLIA-Certified Laboratory NetworkcoreGenetic testing performed in CLIA-certified laboratories ensuring quality, accuracy, and reproducibility. Uses next-generation sequencing technology for comprehensive panel analysis.
Scale indicators8 records
Recent moves6 records
Expansion highlights5 records
LifeShield competitors and assessment
Company assessmentEmerging players
- Function Health: Function Health offers a D2C preventive health membership with broad lab workups and increasingly genetic add-ons. It is an emerging player competing for the same proactive, self-pay consumer and employer-wellness wallet share as LifeShield.
- Forward: Forward Health is a preventive care membership combining diagnostics, AI-driven risk assessment, and concierge primary care. Its AI risk screening and employer/consumer hybrid model overlaps with LifeShield's AI-guided assessment and benefit-style positioning.
- Genome Medical: Genome Medical is a telehealth genetic counseling and clinical genetics service that partners with health systems, employers, and testing labs. It directly parallels LifeShield's genetic counseling and clinical-provider-mediated testing pathway.
Direct peers
- 23andMe: 23andMe is a leading direct-to-consumer genetic testing brand offering BRCA-related reports among broader ancestry and health reports. LifeShield explicitly differentiates against 23andMe on the depth and clinical grade of its hereditary cancer panel, making it the most-cited comparable.
- Color Health: Color Health offers hereditary cancer genetic testing, employer population-health programs, and telehealth genetic counseling. It is the closest direct competitor to LifeShield, operating an almost identical dual D2C + employer benefits GTM with multi-gene panels and CLIA-certified lab infrastructure.
Broad incumbents
- GeneDx: GeneDx is a clinical genetic testing company focused on hereditary cancer, rare disease, and pediatric genetics with a strong clinical-reporting and genetic counseling infrastructure. It overlaps directly with LifeShield's hereditary cancer panel and clinical review workflow.
- Natera: Natera is a specialty genetics company offering hereditary cancer panels alongside reproductive and oncology testing. Its multi-product genetic testing menu and established payer contracts make it a relevant adjacent incumbent competing for the same employer and consumer testing spend.
- Quest Diagnostics: Quest Diagnostics operates one of the largest US clinical lab networks and offers hereditary cancer genetic testing through physician orders. It competes for the same testing volume via in-network reimbursement and established provider relationships.
- Invitae: Invitae is an established clinical genetic testing company offering hereditary cancer panels, proactive screening, and telehealth genetic counseling for patients and providers. It is a broader incumbent that competes with LifeShield's clinical-grade panel and provider-mediated model.
- Myriad Genetics: Myriad Genetics is a long-standing leader in hereditary cancer testing (BRACAnalysis, myRisk) with deep reimbursement relationships and oncologist-driven distribution. It represents the entrenched incumbent that LifeShield's NCCN-based D2C and employer approach attempts to disintermediate.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
LifeShield social profiles
Digital presenceLifeShield financial estimates
Financial estimateRevenue estimate
Valuation estimate
LifeShield leadership team
Management profileNumber of profiles
LifeShield funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
LifeShield M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about LifeShield
What does LifeShield do?
LifeShield operates a hereditary cancer screening platform that combines an AI-guided family cancer history assessment with NCCN clinical guideline-based eligibility analysis, at-home 47-gene hereditary cancer panel testing via CLIA-certified laboratories, and telehealth genetic counseling. The service is delivered direct-to-consumer via lifeshield.ai with a freemium assessment funnel, and as an employer-sponsored wellness benefit priced at $5–15 per eligible employee per month.
Is LifeShield a public or private company?
LifeShield is a private company. It is classified as unknown and is currently operating.
When was LifeShield founded?
LifeShield was founded in 2026. It employs 1 to 10 people.
Where is LifeShield based?
LifeShield is headquartered in New York, United States, in the North America region.
How does LifeShield make money?
Three revenue lines are on record. Direct Genetic Testing is the primary driver. The others are insurance Reimbursement and employer Benefit Program.
Who are LifeShield's main competitors?
Emerging players on record are Function Health, Forward and Genome Medical. Direct peers are 23andMe and Color Health. Broad incumbents are GeneDx, Natera, Quest Diagnostics, Invitae and Myriad Genetics.
Does LifeShield have an API?
No public API is recorded for LifeShield.
What industry is LifeShield in?
LifeShield's product category is Genetic Testing Services. Its primary akta.pro industry code is HLAAALAD, Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics), with a secondary code of HLALAHAK, Genetic Counseling & Prenatal Testing Telehealth (carrier screening, NIPT counseling). Its NAICS code is 541380 and its SIC code is 2835.